Patients with blood cultures positive for gram-positive cocci were enrolled in a prospective randomized double-blind comparative trial of vancomycin at 15 mg/kg every 12 h versus teicoplanin at 6 mg/kg every 12 h for three doses and then 6 mg/kg every 24 h. A total of 54 patients were randomized, and 40 were evaluable. Of the 40, 9 had infection of indwelling vascular catheters. Four infections were due to Staphylococcus aureus, and five were due to Staphylococcus epidermidis. In concert with catheter removal, all patients were treated successfully, regardless of which drug they were taking. Of 31 patients without an indwelling catheter, 19 were infected with S. aureus, and 12 of the 19 had either endocarditis or mycotic aneurysm. Six of eight patients given teicoplanin failed treatment, as opposed to one of four patients given vancomycin (P = 0.14). Of greater concern, four of four patients with left-sided endocarditis or mycotic aneurysm failed to recover when given teicoplanin, as opposed to one of three patients given vancomycin (P = 0.07). Although not quite statistically significant, the unexpectedly high number of treatment failures with teicoplanin resulted in a decision to discontinue patient enrollment. It is suggested that future trials explore the efficacy of larger doses of teicoplanin.
Teicoplanin is a new glycopeptide antibiotic chemically related to the vancomycin-ristocetin group of antibiotics (10, 25) . The teicoplanin MIC for 90% of strains of methicillinsusceptible Staphylococcus aureus is 0.4 pug/ml (19) , and the serum half-life ranges from 40 to 100 h (10, 25) . The long serum half-life and the low MIC for 90% of strains suggest that teicoplanin would be effective in a once-daily dosage regimen against serious infections due to methicillin-susceptible S. aureus.
The average peak concentration in serum after a 3-mg/kg (of body weight) dose of teicoplanin is 7 ,ug/ml, with a trough concentration some 23 h later of 2 ,ug/ml (23) . On the basis of these levels and the in vitro MICs for 90% of strains, the initial clinical trials were conducted with a teicoplanin loading dose of 6 mg/kg and then a once-daily dose of 3 mg/kg. This regimen proved inadequate for severe S. aureus infections (3, 12) . Because of this unfavorable experience, a prospective, randomized, double-blind study was designed to compare a larger teicoplanin dose, i.e., a 12-mg/kg loading dose and then 6 mg/kg/day, with a standard dose of vancomycin of 30 mg/kg/day in the treatment of patients with documented bacteremia due to gram-positive cocci. This report documents the failure of this higher dosage in a subset of enrolled patients with mycotic aneurysm at the site of femoral angiography or left-sided endocarditis. The unexpectedly high number of failures led to a decision to discontinue patient enrollment.
MATERIALS AND METHODS
Patient population. Hospitalized patients 18 years of age or older with blood cultures positive for gram-positive cocci were screened for enrollment in one of two vancomycinversus-teicoplanin protocols: one for patients with infected intravascular access catheters (e.g., Hickman catheters) and one for patients with non-intravascular access-related infection, including endocarditis. Patients were allowed 24 h or less of antibiotic therapy prior to enrollment in the study. Patients were excluded if there was a history of hypersensitivity to vancomycin, pregnancy, presence of a prosthetic heart valve, a serum creatinine level of .2.5 mg/dl, or levels of serum glutamic oxalacetic transaminase and serum glutamic pyruvate transaminase of more than four times normal values. Also excluded were patients with hearing loss sufficient to impair conversation, vestibular dysfunction, or immune deficiency. No patients with infection due to methicillin-resistant S. aureus were enrolled. Each patient was enrolled only once.
Conduct of study. Patients were enrolled either because their symptoms indicated a bacteremic state or because their blood cultures were positive for gram-positive cocci during the first 24 h of hospitalization. If inclusion criteria were met, the patient was enrolled in one of two randomized doubleblind protocols. The blinded investigator obtained informed consent and wrote an order for initiation of the teicoplanin or vancomycin study drug as part of either the vascular access or endocarditis protocol. Then the unblinded investigator used a statistically valid randomization list to assign the patient to either teicoplanin or vancomycin. Randomization was in a 1:1 ratio in uniform blocks of six. Randomization was separate for the two protocols. Patients randomized to teicoplanin received 6 mg/kg every 12 h for three doses and then 6 mg/kg alternating with placebo every (iv) Duration of follow-up. Endocarditis patients were observed for at least 30 days subsequent to the end of teicoplanin or vancomycin therapy. The few exceptions are noted below.
Criteria for catheter-associated infection. Catheter-associated infection was defined as fever and documented bacteremia in the presence of an intravascular access catheter and the absence of any other apparent source of bacteremia. Patients were required to have the vascular access catheter in place at the onset of their febrile illness.
Criteria for intravascular infection: endocarditis and mycotic aneurysm. The criteria used for endocarditis were adopted from Von Reyn et al. as follows: documentation of continuous bacteremia, development of a new regurgitant murmur (tricuspid insufficiency, mitral insufficiency, or aortic insufficiency), presence of definite embolic phenomena, and demonstration of valvular vegetations by echocardiography, surgery, or autopsy (24) . Patients were defined as having definite endocarditis if all criteria were present and probable endocarditis if bacteremia and two of the three other criteria were present.
Patients were considered to have a mycotic aneurysm if there was evidence of continuous bacteremia, emboli distal to the site of arterial involvement, and surgical or histologic confirmation of the presence of a mycotic aneurysm. The patients described below were believed to have femoral mycotic aneurysms as a complication of coronary angiography and not as a complication of endocarditis.
Statistics. Differences in success and failure of treatment regimens were compared by Fisher's exact test for comparison of two proportions. A P value of c0.05 was considered significant.
RESULTS
Over the course of approximately 5 months, 54 patients were enrolled in either the vascular access catheter-associated bacteremia protocol or the bacteremia-endocarditis protocol. Patients were identified by collaborating investigators at four different Portland community teaching hospitals which, along with the University and Veterans hospitals, constitute the Infectious Diseases Consortium of Oregon. Of the 54 patients, 15 were enrolled in the vascular access catheter protocol and 39 were in the bacteremia protocol (Fig. 1) .
Both protocols required 5 days of drug exposure to qualify for assessment of safety and efficacy. There were a variety of reasons patients remained on a protocol for fewer than 5 days. Six patients enrolled in the vascular access protocol were deemed nonevaluable. Four patients were randomized to vancomycin. One patient died of peritonitis after 3 days of therapy. A patient with S. aureus bacteremia died of underlying heart disease after 4 days of treatment. A third patient refused to comply with protocol-required blood sampling and was dropped after 2 days of drug exposure. The last patient had intense facial flushing and pruritus during infusion of the first dose and refused further treatment. Two patients randomized to teicoplanin were nonevaluable. One patient enrolled with a presumptive diagnosis of bacteremic pneumonia proved to have negative blood cultures. The second teicoplanin patient is of interest. The patient was a 75-year-old female with mechanical aortic and mitral valve prostheses. A subclavian catheter was the presumed source of S. aureus bacteremia and meningitis. Blood cultures were positive on day 3 of therapy. The patient remained febrile and died after 4 days of therapy. An autopsy was not allowed.
Eight patients in the non-vascular access protocol were nonevaluable. Of the five vancomycin patients, two had no identifiable gram-positive cocci in the blood. One patient withdrew because of severe preexisting neurosensory hearing loss, one patient with S. aureus bacteremia died because of cardiogenic shock after 4 days, and one patient was switched to intravenous penicillin G after pneumococci were isolated from the blood. Of the three teicoplanin patients, two were judged to have blood cultures contaminated by Staphylococcus epidermidis. The third patient was a 62-year-old male with S. aureus endocarditis. After 4 days, teicoplanin was discontinued and nafcillin was initiated because of a fall in the platelet count to 18,000/mm3. It was unclear whether the thrombocytopenia was due to consumptive coagulopathy caused by the S. aureus bacteremia, the patient's cerebral embolus with hemorrhagic infarction, or an adverse reaction to teicoplanin.
Bacteremia: gram-positive cocci other than S. aureus. Bacteremia due to gram-positive cocci other than S. aureus was identified in 17 patients (Table 1) . Indwelling vascular access catheters infected with S. epidermidis were found in five patients. A Port-a-cath was present in three patients, and a Groshong catheter was present in two patients. Three were treated with teicoplanin, and two were treated with vancomycin. The catheter was removed during the first 5 days of therapy in all patients. Patients received 14 days of therapy, and there were no treatment failures. S. epidermidis bacteremia was encountered in four other patients. One patient had an infected ventriculoatrial shunt and responded to shunt removal and vancomycin. One patient who received teicoplanin became afebrile and had negative blood cultures but died of hepatic failure after only 6 days of teicoplanin therapy. The other two patients had skin diseases as a source and were successfully treated with either vancomycin or teicoplanin.
Endocarditis was present in four patients. Teicoplanin was successful in a patient with Streptococcus viridans mitral valve endocarditis. The other three patients received vancomycin with apparent microbiologic success. The patient with Enterococcqs faecalis endocarditis was treated successfully with a combination of vancomycin and gentamicin. The patient with Streptococcus mutans aortic valve endocarditis responded clinically, and his blood cultures were negative during vancomycin therapy. However, severe aortic insufficiency ne-cessitated emergency valve replacement surgery, which died the presence of sterile vegetations. The patient died postoperatively of heart failure.
The remaining patients all responded to therapy. One received teicoplanin for bacteremic pneumococcal pneumonia. Three received vancomycin: two for bacteremic pneumonia (one each with Streptococcus pyogenes and Streptococcus pneumoniae) and one for E. faecalis bacteremia from an infected third-degree bum.
Overall, teicoplanin was successful in the treatment of 6 patients, and vancomycin was successful in the treatment of 10 patients. Only in the patient with E. faecalis endocarditis was it deemed necessary to add a second anti-infective agent. The result was indeterminate in one teicoplanin patient. Therapy was successful in all patients with prosthesis-related S. epidermidis infections.
S. aureus bacteremia without intravascular infection. S. aureus bacteremia was identified in 11 patients who did not have evidence of intravascular infection ( was achieved with the addition of rifampin. Two teicoplanin patient was successfully treated with surgical debridement of patients with osteomyelitis are of interest. One patient with the sternum and continued therapy with teicoplanin alone. vertebral osteomyelitis 'enjoyed a prompt response to teico-S. aureus endocarditis and mycotic aneurysm. Endocarditis planin. The second patient was post-aortocoronary bypass or mycotic aneurysm was present in 12 patients (Table 3) . surgery and had bacteremic staphylococcal pneumonia. DurNo patient had both infections. Of the eight patients randoming teicoplanin therapy, it became apparent that the sternum ized to teicoplanin, six failed on the basis of some combinawas also infected. Whether the sternum infection occurred tion of documented ongoing S. aureus infection at a nonvasbefore or after initiation of teicoplanin is unknown. The cular site, "breakthrough bacteremia," or the need to add two or more antimicrobial agents because of protracted bacteremia. By comparison, of four patients randomized to vancomycin, there were three successes and one failure. The difference in the proportion of patients achieving success did not quite achieve statistical significance (P = 0.14). Five patients had tricuspid valve endocarditis due to intravenous (i.v.) drug abuse. Of the four given teicoplanin, two failed because of the need to modify the treatment regimen; the one patient administered vancomycin was treated successfully (P = 0.81).
The patients with left-sided endocarditis or mycotic aneurysm were grouped together because of the similarities of the pathologic process, their greater ages, and the frequency of serious concomitant underlying diseases. Four patients were randomized to teicoplanin, and all four failed. Three patients were administered vancomycin, and one patient failed. Despite the small numbers, the results were close to statistical significance (P = 0.07).
Clinical summaries. A brief clinical description is provided of the five patients who failed either teicoplanin or vancomycin treatment for left-sided endocarditis or mycotic aneurysm.
(i) Patient 1. A 63-year-old male underwent percutaneous right transfemoral coronary arteriography followed immediately by coronary angioplasty. Within 24 h he became febrile, with blood cultures positive for S. aureus. After the culture results were known, the patient was randomized to teicoplanin. Because the blood cultures remained positive for the next 3 days, tobramycin at a standard dosage was added. Blood cultures were positive during dual therapy for another 5 days. Embolic phenomena in the distal right leg were noted. Subsequent surgery documented the presence of a right femoral artery mycotic aneurysm. Postsurgery, the patient's temperature returned to normal within 2 days. Combined therapy was continued for 30 days after surgery.
At the end of therapy and over the ensuing 2 weeks, the patient complained increasingly of midback pain. Subsequently, the presence of T8-T9 S. aureus vertebral osteomyelitis was documented radiographically and bacteriologically. Following 6 weeks of i.v. nafcillin therapy, the patient made an uneventful recovery.
(ii) Patient 2. A 55-year-old male entered the hospital with S. aureus bacteremia and was randomized to receive teicoplanin. Because of extreme clinical toxicity and the presence of a mitral insufficiency murmur, an aminoglycoside was added on the second day of therapy. The patient required surgical drainage and debridement of an infected right sternoclavicular joint on the fourth day of therapy. Blood cultures were documented as positive for S. aureus through 5 days of treatment but were negative on day 6, which was 1 day postdebridement.
Over the subsequent 2 weeks, the patient was largely afebrile but complained of persistent pain at the right sternoclavicular joint. In addition, pain developed in the left first toe, and parietal-occipital headaches became more severe. After 21 days of combined therapy with teicoplanin and tobramycin, S. aureus osteomyelitis of the proximal phalanx of the left first toe was documented surgically, cultures of the previously debrided sternoclavicular joint were still positive, and computerized tomographs of the head demonstrated abnormalities compatible with multiple parietal-lobe brain abscesses.
The patient was declared a clinical and bacteriologic failure. The study drug regimen was discontinued, and therapy was instituted with a combination of nafcillin, rifampin, and tobramycin. The tobramycin was discontinued after 1 week, and the nafcillin plus rifampin was continued for 1 month, during which time all evidence of active infection disappeared.
Six months after completing therapy, the patient required 22 ,ug/ml, with a range of 15 to 31 p,g/ml, and the mean trough concentration was 8 ,ug/ml, with a range of 5 to 14 ,ug/ml. Even though three of the four patients given teicoplanin for right-sided endocarditis had successful therapy, their serum drug levels were no higher than those of the four patients who failed treatment for left-sided endocarditis or mycotic aneurysm.
For the four patients given vancomycin for intravascular infection, the mean peak concentration was 23 p,g/ml, with a range of 16 to 34 pg/ml, and the mean trough concentration was 8 ,ug/ml, with a range of 6 to 9 ,ug/ml. Since only four patients were given vancomycin, it was not possible to correlate concentrations in serum with clinical success or failure.
In vitro microbiologic studies. All S. aureus isolates from patients enrolled in the study were susceptible in vitro to both vancomycin and teicoplanin. In those patients with persistent bacteremia or breakthrough bacteremia, all isolates remained susceptible in vitro; in vivo emergence of resistance was not identified in vitro. Adverse effects. Possible drug-related adverse effects occurred in two patients during the first 5 days of therapy. One patient had immediate flushing during the infusion of the first dose of vancomycin. The second patient developed thrombocytopenia after 4 days of teicoplanin administration. DISCUSSION We are aware that the design of this study was not perfect. Modification of the antibiotic regimen should have been stipulated in the protocol with respect to specific indications, e.g., persistent fever or bacteremia for a defined period, and with respect to specific antibiotics and their dosage regimens. Six of the 12 patients with intravascular infection received a modified antibiotic regimen; 5 of the 6 patients were receiving teicoplanin. The addition of an aminoglycoside antibiotic or rifampin is consistent with the way teicoplanin has been prescribed by European investigators, as discussed below (8, 9, 16) .
The major issue is the small number of S. aureus endocarditis patients. Because of the observed high failure rate, enrollment was interrupted after 12 patients so as to conduct an interim analysis. Even with the small numbers, the failure rate of teicoplanin in patients with left-sided endocarditis or mycotic aneurysm almost achieved statistical significance (P = 0.07). We projected a continuing zero success rate with teicoplanin and a 66% success rate with vancomycin. Under these conditions, it would have required the addition of two patients treated with teicoplanin and three patients treated with vancomycin to achieve a P value of less than 0.05 and avoid a possible type II statistical error with a power of 90%. Despite the projected need for only a few additional patients to achieve statistical significance, the investigators were unanimous in their opinion that continuing the study was ethically unacceptable. It was considered dishonest to approach a patient, or patient surrogate, without disclosing that the relevant literature indicated a bacteriologic cure rate of 82% or better with nafcillin (15) and perhaps 70% with vancomycin (10, 16) but that our overall success with teicoplanin was only 25% (Table 4) .
The percent cure rates in Table 4 are based on our definitions. Success or cure was defined as resolution of fever and documentation of negative blood cultures. Documentation of valve destruction or the need for surgical correction of valvular insufficiency was not considered evidence of failure of the antibiotic efficacy of a drug regimen. Examples of failure of antibacterial activity include presence of perivalvular abscess formation, resected vegetations with evidence of active infection, and necrotic inflamed myocardium.
The results of Korzeniowski et al. (15) were interpreted using our definitions. In addicts, all 22 patients given nafcillin alone were cured (10lo); of the 22 evaluable patients given nafcillin and gentamicin, 21 of 22 were cured (96%). The nonaddicts were older, had more concomitant disease, and did not fare as well. Of the 11 patients given nafcillin alone, 9 were treated successfully (82%). An elderly female died 12 h after admission with documented S. aureus bacteremia and meningitis. The second failure was manifest as an immediate posttreatment relapse. Nafcillin plus gentamicin was given to 19 patients, and 16 responded (849%). The failures were documented by perivalvular abscesses (one patient), positive abscess cultures (one patient), and necrosis of the interventricular septum (one patient). Three other patients died as a result of noninfectious complications of documented endocarditis. In short, nafcillin was highly efficacious. Despite a wealth of clinical experience, there are few published studies on the efficacy of vancomycin in the treatment of S. aureus endocarditis (4, 5, 11, 17, 21) . The anticipated success with vancomycin or teicoplanin may differ with the patient population. Small and Chambers found an unexpectedly complicated or unsatisfactory clinical response in 5 of 13 patients (38%) with S. aureus endocarditis in association with i.v. drug use (21) . The same authors reviewed the literature and found reported failure rates of 0 to 12% and relapse rates of 0 to 12% (21). Levine et al. also focused on the addict population but included only patients with methicillin-resistant S. aureus (17) . In many patients, there was a delay in recognition of methicillin-resistant S. aureus which contributed to the reported large range in the number of days of bacteremia. The clinical and bacteriologic success rate of Levine et al., 68%, is close to our 75% and substantially lower than the nafcillin rate. Furthermore, the vancomycin success rate was substantially greater than the rates we achieved with teicoplanin.
Our experience with teicoplanin given at a loading dose of 12 mg/kg and then 6 mg/kg/day is similar to published reports of failure with a regimen which consisted of a loading dose of 6 mg/kg and then 3 mg/kg/day (3, 12) . The authors of the previously published studies called for trials of either combination therapy or a higher dose of teicoplanin. Published European clinical trials which report teicoplanin efficacy in the 3-to 6-mg/kg/day dosage range used teicoplanin as a part of a two-or three-antibiotic treatment regimen (8, 9) . For example, in one trial of empiric therapy in febrile neutropenic leukemia patients, amikacin-plus-ceftazidime regimens with and without teicoplanin were compared (9) .
More recently, the efficacy of a higher teicoplanin dose with a concomitantly administered aminoglycoside was assessed in patients with endocarditis (16) . A once-daily teicoplanin dose was adjusted to maintain peak levels of between 40 and 50 1ig/ml; the resultant mean daily dosage was 7 (26) . The protein-binding effect may be amplified in vivo by the known lipophilicity of teicoplanin (10, 23) . It is tempting to speculate that some part of the 10% of the drug that is free may be deposited in fat depots and be unavailable to exert action against intravascular bacteria.
An inoculum effect has been demonstrated in vitro by ourselves and others (13, 14, 20) . The in vitro activity of vancomycin is also characterized by an inoculum effect, but it is more modest than that of teicoplanin (13, 14) .
Teicoplanin treatment of endocarditis in animal models might answer some of the above questions. In rabbits with S. epidermidis aortic valve endocarditis, teicoplanin at the dosage tested (30 mg/kg once daily) sterilized the vegetations of only 1 of 14 rabbits compared with 8 of 12 rabbits when rifampin was added (22) . No levels of teicoplanin in serum were measured. Contrepois et al. compared teicoplanin to vancomycin in a rabbit model of S. aureus endocarditis (6) . The drugs were given intramuscularly (i.m.), with a vancomycin dosage of 9 mg/kg and a teicoplanin dosage of 4.5 mg/kg. The vancomycin was administered every 12 h, while the teicoplanin was given every 16 or 24 h. The vancomycin regimen proved most efficacious, while the every-16-h teicoplanin regimen was superior to the 24-h dosage regimen. Chambers and Kennedy studied the influence of peak and trough concentrations in serum on the efficacy of teicoplanin in a rabbit model of aortic valve endocarditis (4). An identical teicoplanin dosage, a 36-mg/kg loading dose and then 18 mg/kg every 12 h, was administered by either the i.v. or i.m. route. The i.v. regimen resulted in much higher peak concentrations in serum but was less effective than i.m. administration, which had higher trough concentrations. It is possible that the i.m. route resulted in more time for the 10% of drug free from protein binding to penetrate infected vegetations. No published study has addressed the issue of the efficacy of increasing doses of teicoplanin in animals or patients with endocarditis.
Another possible explanation for failure is lack of contact between the infecting bacteria and the antibiotic. Cremeux et al. used autoradiographic techniques to demonstrate the degree of penetration of selected antibiotics into the aortic valve vegetation of rabbits with experimental streptococcal endocarditis (7). The major finding was the difference in the distributions of antibiotic within the vegetation: tobramycin was distributed evenly; penicillin was more concentrated at the periphery but still reached the center of the vegetations; but, for reasons not understood, teicoplanin was concentrated only at the periphery of the vegetations.
None of these variables explains a differential success of teicoplanin in patients with S. aureus right-sided endocarditis as opposed to left-sided endocarditis. Bayer at al. raised the interesting possibility of different antibiotic pharmacokinetics and pharmacodynamics in vegetations on the right and left sides (1) .
Despite the frequency of transfemoral cardiac catheterization studies, the development of a mycotic aneurysm at the site of transfemoral percutaneous angioplasty is a rare event. Brummitt et al. recently reported on three patients and found an additional four cases in the literature (2) . One or several technical factors related to the details of the procedure may explain the increased recognition of this problem, e.g., protracted dwell time of the catheter sheath, size of the sheath, and removal and replacement of the catheter postangiogram and preangioplasty.
In summary, a carefully controlled, blinded study assessed the comparative efficacy of teicoplanin and vancomycin in patients with S. aureus endocarditis or endarteritis. Although the numbers of patients were small and vancomycin treatment failed for one patient, teicoplanin treatment failed for four of four consecutive patients with left-sided endocarditis or mycotic aneurysms. These failures resulted in a decision to terminate the clinical trial. Although not quite achieving clinical significance, the high failure rate with teicoplanin led us to conclude that the drug was a failure with the dosage regimen employed. It is possible that greater efficacy may occur with a dosage regimen that achieves higher concentrations in serum.
